Show simple item record

dc.contributor.authorBarrington, S F
dc.contributor.authorQian, W
dc.contributor.authorSomer, E J
dc.contributor.authorFranceschetto, A
dc.contributor.authorBagni, B
dc.contributor.authorBrun, E
dc.contributor.authorAlmquist, H
dc.contributor.authorLoft, A
dc.contributor.authorHøjgaard, L
dc.contributor.authorFederico, M
dc.contributor.authorGallamini, A
dc.contributor.authorSmith, P
dc.contributor.authorJohnson, P
dc.contributor.authorRadford, John A
dc.contributor.authorO'Doherty, M J
dc.date.accessioned2010-11-18T15:48:02Z
dc.date.available2010-11-18T15:48:02Z
dc.date.issued2010-10
dc.identifier.citationConcordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. 2010, 37 (10):1824-33 Eur. J Nucl Med Mol Imagingen
dc.identifier.issn1619-7089
dc.identifier.pmid20505930
dc.identifier.doi10.1007/s00259-010-1490-5
dc.identifier.urihttp://hdl.handle.net/10541/115846
dc.description.abstractPURPOSE: To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. METHODS: Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites involved at diagnosis that was higher than mediastinal uptake represented disease (sensitive reading). RESULTS: There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44 patients with a conservative reading and in 41 patients with a sensitive reading. Kappa was 0.85 (95% CI 0.74-0.96) for conservative reading and 0.79 (95% CI 0.67-0.90) for sensitive reading. Agreement was reached in 46 and 44 patients after discussion for the conservative and sensitive readings, respectively. CONCLUSION: The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.
dc.language.isoenen
dc.subjectHodgkin Lymphomaen
dc.subjectTreatmenten
dc.titleConcordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.en
dc.typeArticleen
dc.contributor.departmentPET Imaging Centre at St Thomas', Kings College London Division of Imaging, Lambeth Palace Road, London SE1 7EH, UK. sally.barrington@kcl.ac.uken
dc.identifier.journalEuropean Journal of Nuclear Medicine and Molecular Imagingen
html.description.abstractPURPOSE: To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between 'core' laboratories operating in different countries. METHODS: Four centres reported scans from 50 patients with stage II-IV HL, acquired before and after two cycles of Adriamycin/bleomycin/vinblastine/dacarbazine. A five-point scale was used to score response scans using 'normal' mediastinum and liver as reference levels. Centres read scans independently of each other. The level of agreement between centres was determined assuming (1) that uptake in sites involved at diagnosis that was higher than liver uptake represented disease (conservative reading), and (2) that uptake in sites involved at diagnosis that was higher than mediastinal uptake represented disease (sensitive reading). RESULTS: There was agreement that the response scan was 'positive' or 'negative' for lymphoma in 44 patients with a conservative reading and in 41 patients with a sensitive reading. Kappa was 0.85 (95% CI 0.74-0.96) for conservative reading and 0.79 (95% CI 0.67-0.90) for sensitive reading. Agreement was reached in 46 and 44 patients after discussion for the conservative and sensitive readings, respectively. CONCLUSION: The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.


This item appears in the following Collection(s)

Show simple item record